SINGAPORE - People who are eligible for the Novavax Covid-19 vaccine can go to selected clinics from Jan 24 to April 30 for ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Moderna stock surged Wednesday after Oracle Chairman Larry Ellison praised the potential of AI in developing medicines.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Dr. Paul Hunter, a professor of medicine at Britain’s University of East Anglia, described the mRNA vaccines made by BioNTech-Pfizer and Moderna Inc. as a “game changer” in shutting down the ...

Moderna's technology focuses on helping the body create specific messenger RNA, or mRNA. When the mRNA sees ... Moderna sells ...

Both the Moderna and Pfizer/BioNTech actions are being heard in a Delaware district court. The lawsuits contribute to an ongoing bun fight between various parties involved in mRNA vaccines ...

BioNTech and Regeneron are competing with rivals Moderna and MSD in the mRNA ... PD-1 inhibitor Keytruda (pembrolizumab). mRNA-4157 is a personalised vaccine targeting 34 cancer neoantigens ...

The First Amendment's guarantees are not absolute. A person cannot “shout 'fire!' in a crowded theater,” and put the lives of ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready ...